WE DISCOVER AND DEVELOP NOVEL AND

DIFFERENTIATED THERAPIES IN CANCER AND BEYOND

ADDRESS UNMET MEDICAL NEEDS FOR PATIENTS IN CHINA AND GLOBALLY

Founded in 2016, we have established a robust in-house R&D engine underpinned by an outstanding discovery team and a multi-dimensional discovery platform. We have strategically designed and developed a rich pipeline of 10+ small molecule programs focused on oncology.

01---

Founders

-------------------------------------------------

Our company was founded by a group of experienced drug hunters with strong passion, proven track records in drug discovery, and rich experience in managing multiple large R&D organizations.

Dr. Yao-Chang Xu

Founder & CEO

Dr. Yao-Chang Xu

Founder & CEO

Dr. Yao-Chang Xu has more than 25 years of drug dis...

Dr. Hongping Yu

Co-founder, CSO

Dr. Hongping Yu

Co-founder, CSO

Dr. Hongping Yu has worked in drug discovery and de...

Dr. Zhui Chen

Co-founder, CSO

Dr. Zhui Chen

Co-founder, CSO

Dr. Zhui Chen is a seasoned biologist and drug hunt...

Our Scientific Focus

small molecule precision oncology & immuno-oncology therapies

Our Pipeline

Consists of a broad range of small-molecule
precision-oncology and immuno-oncology product candidates

Partnership

We have established and continue to explore broad partnership

and collaboration with industry and academic leaders

News Press

News

Clinical Trial of Next-Generation EGFR Inhibitor AB...

September 24 2024,Abbisko Therapeutics (HKEX code: 02256) announced thatthe China National Medical Pr...

Abbisko awarded Best Poster Award at ESMO Congress ...

Abbisko Therapeutics (HKEX: 02256) is excited to announce the receipt of theESMO 2024 Best Poster Awa...

Abbisko Therapeutics Presents Updated Clinical Prog...

September 15, 2024, Abbisko Therapeutics (HKEX: 02256) presents updated clinical safety and efficacy ...

Press

PharmaBoardroom interviews Dr. Xu Yaochang, the fou...

Yao-Chang Xu – Founder & CEO, Abbisko “Partnering with a multinational like Merck not only accele...

Bioworld: Abbisko out-licenses pimicotinib to Merck...

Abbisko Therapeutics Co. Ltd. has out-licensed China rights to its colony-stimulating factor 1 recept...

Endpoints: Abbisko signs $70M upfront deal with Mer...

Shanghai-based Abbisko Therapeutics has lined up another partner for its oncology pipeline and will r...

VISION & MISSION

We aspire to become a leading biopharmaceutical company to discover and develop novel and differentiated therapies in cancer and beyond, addressing critical unmet needs for patients in China and globally.

Investors

Since our establishment, we have completed four rounds of financing led by blue-chip investors. Our investor base is a testament to our capabilities and provides strong financial supports and industry insights to our future success.